Home > Dermatology > EADV 2019 > Emerging Therapies > Biologics: increasingly used in paediatric dermatology

Biologics: increasingly used in paediatric dermatology

Expert
Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands
Conference
EADV 2019

Biologics and cytokine blockers are increasingly used in children and adolescents with moderate-to-severe psoriasis and atopic dermatitis (AD). Data shows that they cause less side effects than systemic conventional therapies [1].

In adults, biologics targeting specific cytokines are effective, well tolerated, and a safe alternative to conventional systemic treatments. At present, 3 biologics (i.e. etanercept, adalimumab, and ustekinumab) are approved in paediatric psoriasis and dupilumab is approved in AD.

TNF-blockers and ustekinumab showed similar efficacy and tolerability compared with trials in an adult population [2-4]. In the meantime, long-term data from open-label extensions with TNF-blockers showed reassuring results. After 5 years, etanercept was still well tolerated and efficacy was maintained in those who remained in the study for up to 264 weeks [5]. There were no opportunistic infections or malignancies. Similarly, 52-week data from a...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on